MON-370 Cardiovascular Risk Factors, Adiponectin, Resistin and Plasminogen Activator Inhibitor-1 in Patients with Graves’ Disease, Hashimoto Thyroiditis and Nontoxic Multinodular Goiter

Abstract Disclosure: C. Neves: None. J. Neves: None. O. Sokhatska: None. M. Pereira: None. J. Queirós: None. L. Delgado: None. Introduction: Adipocyte dysfunction can alter adipokine profile contributing to metabolic and cardiovascular risk. Our aim was to evaluate the relationship between thyroid function, autoimmunity, inflammation, lipid profile, adiponectin, resistin and plasminogen activator inhibitor-1 (PAI-1) in patients with Graves’ disease (GD), Hashimoto thyroiditis (HT) and nontoxic multinodular goiter (MNG). Methods: We analyzed thyroid function, BMI, and the levels of total cholesterol (TC), HDL, LDL-cholesterol, triglycerides, ApoB, ApoA1, Lp(a), homocysteine, folic acid, vitamin B12, high sensitivity C reactive protein (hs-CRP), adiponectin, resistin and PAI-1 levels in 30 patients with GD, 35 with HT, and 33 with MNG. Statistical analysis was performed using ANOVA, Student’s t-test, and the Spearman’s correlation test. Results are expressed as mean ± standard deviation. A two-tailed p<0.05 was considered statistically significant. Results: There were no significant differences in age between MNG (50±16 years), HT (46±17 years) and GD groups (44±13 years) and sex (90.0%, 97.1% and 90.9% females, respectively). The levels of resistin were significantly higher in HT group compared with MNG group (20.7±22.6 vs 19.3±9.0, p=0.05) and with GD group (20.7±22.6 vs 12.7±10.9 ng/ml, p<0.01). Significantly higher levels of PAI-1 were observed in HT group compared to MNG group (27.3±25.1 vs 18.7±11.8 ng/ml, p<0.01) and GD group (27.3±25.1 vs 19.9±17.4 ng/ml, p<0.01). Patients with HT presented significantly lower levels of adiponectin than GD group (21.0±13.3 vs 28.3±14.7 µg/ml, p<0.01). There were no correlations between BMI and adiponectin, resistin or PAI-1. Resistin levels were not correlated with TSH, FT3 or FT4. PAI-1 levels were negatively correlated with FT3 in both HT (r=-0 .42, p<0.05) and GD groups (r=-0.36, p<0.05). Adiponectin levels were negatively correlated with FT3 in GD group (r=-0.35, p<0.05) and with TSH in MNG group (r=-0.61, p<0.001). Serum levels of hs-CRP were significantly elevated in HT group compared to MNG group (0.56±0.55 vs 0.30±0.24, p<0.001). Conclusions: Our study highlights significant alterations in adipokine profiles, particularly elevated resistin and PAI-1 levels, in patients with Hashimoto thyroiditis compared to those with Graves' disease and MNG. These findings suggest a potential role of thyroid function and autoimmune thyroid disorders in modulating adipokine levels, which may contribute to the increased metabolic and cardiovascular risk. Presentation: Monday, July 14, 2025